T2 Biosystems, Inc. (TTOO)

Overview

T2 Biosystems, Inc. is an in vitro diagnostics company that focuses on the development of diagnostic products and candidates, operating both in the United States and internationally. The company's innovative technology is designed for the detection of pathogens, biomarkers, and various abnormalities directly from an array of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. Since its establishment in 2006, with headquarters in Lexington, Massachusetts, T2 Biosystems has been at the forefront of transforming the diagnostics landscape by providing faster, more reliable results that can critically impact patient care and outcomes.

Products and Services

• T2Dx Instrument - This is a bench-top instrument capable of running multiple diagnostic tests directly from patient samples. The T2Dx Instrument streamlines the diagnostic process, enabling rapid and accurate results without the need for sample purification.
• T2Candida Panel - A direct-from-blood test that identifies bloodstream infections leading to sepsis and candidemia. This panel is crucial for the fast detection of these serious conditions, enabling timely treatment.
• T2Bacteria Panel - This panel detects bacterial pathogens associated with sepsis directly from blood. By bypassing the cultivation step, it significantly reduces the time to result, which is vital for patients with sepsis.
• T2Resistance Panel - A direct-from-blood test designed to identify carbapenem resistance genes. This is critical in managing antibiotic resistance by accurately identifying resistant infections, allowing for appropriate antibiotic stewardship.
• T2SARS-CoV-2 Panel - Developed to detect the SARS-CoV-2 virus, this panel supports the ongoing global effort to manage and mitigate the spread of COVID-19 through timely and accurate diagnostics.

In addition to these products, T2 Biosystems is committed to advancing diagnostic technologies with several products under development:

• T2Biothreat Panel - A panel for the detection of biothreat pathogens. This development highlights T2 Biosystems’ efforts in enhancing biosecurity through fast and reliable detection methodologies.
• Comprehensive Sepsis Panel - This panel is under development to enable detection of bloodstream infections caused by bacterial and Candida species, along with antibiotic-resistant markers. Its comprehensive nature aims to improve sepsis management by offering a broader spectrum of detection.
• T2Cauris Panel - Aimed at providing direct detection of the emerging superbug Candida auris in various samples including patient skin, blood, and environmental samples from healthcare settings. This panel addresses the growing need for monitoring and controlling hospital-acquired infections.
• T2Lyme Panel - A direct-from-blood test panel being developed for the T2Dx Instrument to identify the bacteria that cause Lyme disease, offering a more direct approach in diagnosing this condition.